About this template
The Industry — Pharma template is a regulated CV set in Manrope and Inter with JetBrains Mono micro-labels and a clinical green accent. Sections map GxP environments — clinical phases, regulatory submissions (FDA, EMA, MHRA), publications and therapeutic areas — without descending into ATS austerity. It registers with big-pharma recruiters as well as listed biotechs.
Who is it for?
It suits medical-affairs, regulatory-affairs, clinical-operations, pharmacovigilance and quality leaders applying to Pfizer, Merck, Johnson & Johnson Innovative Medicine, AbbVie, Eli Lilly, Bristol Myers Squibb, GSK, AstraZeneca, Novartis, Roche, Sanofi and the CROs (ICON, Parexel, Syneos Health, Labcorp Drug Development). Equally relevant for market-access, HEOR and value-and-access profiles targeting US payor strategy or EU HTA bodies.
How to use it
Structure roles by therapeutic area (oncology, immunology, neuroscience, rare disease, cardiometabolic, vaccines) and clinical phase (I, IIa, IIb, III, IV, life-cycle management). List submissions you contributed to (IND, NDA, BLA, MAA, sNDA) with role and outcome (approved, withdrawn, in review, refusal letter). Name the standards (ICH-GCP E6 R2, ICH-GMP, 21 CFR Part 11, ISO 14155, GVP Module V) and inspections you prepared for (FDA PAI, EMA, MHRA, ANSM, PMDA) with results.
Frequently asked questions
Should I name compounds still under embargo?
Until a compound enters clinical-trial public registries (ClinicalTrials.gov, EU Clinical Trials Register, ChinaDrugTrials), describe by target or class ('kinase inhibitor, solid-tumour oncology') without naming the compound. After IND or first EMA submission, the compound is public — list it by code name (e.g. PF-06882961) per the disclosed registry.
How do I describe a successful FDA or EMA inspection?
State the inspection type (PAI, BIMO, GMP, GCP, GPvP), year, jurisdiction and outcome (NAI no action indicated, VAI voluntary action indicated, OAI official action indicated). Regulatory and compliance recruiters at big pharma value inspection experience enormously — it is a seniority signal that cannot be fabricated and is verified during reference checks.
Does it fit medical-device applications?
Yes with adaptation. Medical devices fall under MDR (EU) and 510(k)/PMA (FDA), not the drug framework. Replace clinical phases with device classes (Class I, IIa, IIb, III) and IND/NDA submissions with 510(k), De Novo or PMA. Recruiters at Medtronic, Stryker, Boston Scientific and Edwards Lifesciences recognise and reward the adaptation effort.
